• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply.

作者信息

Steffen Robert, DuPont Herbert L

机构信息

University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Hirschengraben 84, Zurich, CH, Switzerland.

The University of Texas-Houston School of Public Health and Medical School, Center for Infectious Diseases, 6720 Bertner MC1-164, Houston, TX, USA.

出版信息

J Travel Med. 2019 May 10;26(3). doi: 10.1093/jtm/taz014.

DOI:10.1093/jtm/taz014
PMID:30848824
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6509471/
Abstract
摘要

相似文献

1
Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply.利福霉素SV-MMX®作为中度至重度旅行者腹泻的推荐自我治疗药物：回复
J Travel Med. 2019 May 10;26(3). doi: 10.1093/jtm/taz014.
2
Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.利福昔明 MMX 治疗旅行者腹泻：与环丙沙星同样有效，且不与耐药菌的产生相关。
J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay116.
3
When should travel medicine practitioners prescribe Rifamycin SV-MXX for self-treatment of travellers' diarrhoea?旅行医学从业者应在何时开利福霉素SV-MXX用于旅行者腹泻的自我治疗？
J Travel Med. 2019 May 10;26(3). doi: 10.1093/jtm/taz013.
4
Antibiotics for Travellers' Diarrhoea on Trial-is there a potential role for Rifamycin SV?用于旅行者腹泻试验的抗生素——利福霉素SV有潜在作用吗？
J Travel Med. 2019 Jan 1;26(1). doi: 10.1093/jtm/tay137.
5
Development of a new travellers' diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy.旅行者腹泻临床严重程度新分类的制定及其在确认利福昔明疗效中的应用。
J Travel Med. 2023 Oct 31;30(6). doi: 10.1093/jtm/taad043.
6
Rifamycin SV MMX: A Review in the Treatment of Traveller's Diarrhoea.利福昔明 MMX：旅行者腹泻治疗中的一个综述。
Clin Drug Investig. 2019 Jul;39(7):691-697. doi: 10.1007/s40261-019-00808-2.
7
Rifamycin SV MMX for the treatment of traveler's diarrhea.利福霉素SV MMX用于治疗旅行者腹泻。
Expert Opin Pharmacother. 2017 Aug;18(12):1269-1277. doi: 10.1080/14656566.2017.1353079. Epub 2017 Jul 27.
8
In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.利福昔明对从返回英国的旅行者中分离出的临床大肠杆菌和其他肠致病性细菌的体外活性。
Int J Antimicrob Agents. 2014 May;43(5):431-7. doi: 10.1016/j.ijantimicag.2014.01.026. Epub 2014 Mar 1.
9
Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.利福昔明靶向结肠治疗旅行者腹泻的随机、双盲、安慰剂对照 3 期研究。
J Travel Med. 2014 Nov-Dec;21(6):369-76. doi: 10.1111/jtm.12168.
10
Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea.综述文章：利福昔明，一种极少被吸收的口服抗菌药物，用于治疗旅行者腹泻。
Aliment Pharmacol Ther. 2010 Jun;31(11):1155-64. doi: 10.1111/j.1365-2036.2010.04296.x. Epub 2010 Mar 11.

引用本文的文献

1
Travel-related gastrointestinal diseases: Assessment and management.旅行相关的胃肠疾病：评估与管理
Public Health Chall. 2022 Nov 2;1(4):e30. doi: 10.1002/puh2.30. eCollection 2022 Dec.
2
Current State and Promising Opportunities on Pharmaceutical Approaches in the Treatment of Polymicrobial Diseases.治疗多种微生物疾病的药物方法的现状与潜在机遇
Pathogens. 2021 Feb 20;10(2):245. doi: 10.3390/pathogens10020245.
3
Health risk of travel for chronic kidney disease patients.慢性肾病患者旅行的健康风险。
J Res Med Sci. 2020 Mar 18;25:22. doi: 10.4103/jrms.JRMS_459_18. eCollection 2020.

本文引用的文献

1
Emergence of Resistance to Quinolones and β-Lactam Antibiotics in Enteroaggregative and Enterotoxigenic Causing Traveler's Diarrhea.肠聚集性和肠毒性导致旅行者腹泻的耐喹诺酮类和β-内酰胺类抗生素的出现。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01745-18. Print 2019 Feb.
2
Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.利福昔明 MMX 治疗旅行者腹泻：与环丙沙星同样有效，且不与耐药菌的产生相关。
J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay116.
3
Trial Evaluating Ambulatory Therapy of Travelers' Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide.旅行者腹泻（TrEAT TD）门诊治疗评估试验：比较洛哌丁胺与 3 种单剂量抗生素方案的随机对照试验
Clin Infect Dis. 2017 Nov 29;65(12):2008-2017. doi: 10.1093/cid/cix693.
4
Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.旅行者腹泻防治指南：一份分级专家小组报告。
J Travel Med. 2017 Apr 1;24(suppl_1):S57-S74. doi: 10.1093/jtm/tax026.
5
Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.利福昔明靶向结肠治疗旅行者腹泻的随机、双盲、安慰剂对照 3 期研究。
J Travel Med. 2014 Nov-Dec;21(6):369-76. doi: 10.1111/jtm.12168.
6
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.一项随机、双盲、多中心研究，比较利福昔明与安慰剂及环丙沙星治疗旅行者腹泻的效果。
Am J Trop Med Hyg. 2006 Jun;74(6):1060-6.
7
Epidemiology of travelers' diarrhea: details of a global survey.旅行者腹泻的流行病学：一项全球调查的细节
J Travel Med. 2004 Jul-Aug;11(4):231-7. doi: 10.2310/7060.2004.19007.